Sharon Fong

3.3k total citations · 1 hit paper
11 papers, 2.7k citations indexed

About

Sharon Fong is a scholar working on Molecular Biology, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Sharon Fong has authored 11 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Molecular Biology, 4 papers in Oncology and 4 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Sharon Fong's work include Cell death mechanisms and regulation (5 papers), Monoclonal and Polyclonal Antibodies Research (3 papers) and Cancer Research and Treatments (2 papers). Sharon Fong is often cited by papers focused on Cell death mechanisms and regulation (5 papers), Monoclonal and Polyclonal Antibodies Research (3 papers) and Cancer Research and Treatments (2 papers). Sharon Fong collaborates with scholars based in United States, France and Cuba. Sharon Fong's co-authors include Ralph Schwall, David A. Lawrence, Avi Ashkenazi, Hartmut Koeppen, Jeanine L. Bussiere, Scot A. Marsters, Andrea Hebert, Zahra Shahrokh, Laura DeForge and Iphigenia L. Koumenis and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Investigation and Nature Medicine.

In The Last Decade

Sharon Fong

11 papers receiving 2.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Safety and antitumor activity of recombinant soluble Apo2 ligand

1999 1.9k citations Avi Ashkenazi, Sharon Fong et al. Journal of Clinical Investigation profile →

Peers

Countries citing papers authored by Sharon Fong

Since Specialization

Citations

This map shows the geographic impact of Sharon Fong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sharon Fong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sharon Fong more than expected).

Fields of papers citing papers by Sharon Fong

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sharon Fong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sharon Fong. The network helps show where Sharon Fong may publish in the future.

Co-authorship network of co-authors of Sharon Fong

This figure shows the co-authorship network connecting the top 25 collaborators of Sharon Fong. A scholar is included among the top collaborators of Sharon Fong based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sharon Fong. Sharon Fong is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

#	Work	Indexed citations
1	Comparison of the Efficacy of N9 Neuraminidase-Specific Monoclonal Antibodies against Influenza A(H7N9) Virus Infection 2017 ·Journal of Virology ·Hongquan Wan, Li Qi, Jin Gao, Laura Couzens, Lianlian Jiang, Yamei Gao, Zong‐Mei Sheng, Sharon Fong, Megan Hahn, Surender Khurana, Jeffery K. Taubenberger, Maryna C. Eichelberger	19
2	Cooperation of the Agonistic DR5 Antibody Apomab with Chemotherapy to Inhibit Orthotopic Lung Tumor Growth and Improve Survival 2008 ·Clinical Cancer Research ·Hongkui Jin, Renhui Yang, Jed Ross, Sharon Fong, Richard A.D. Carano, Klára Tótpál, David A. Lawrence, Zhong Zheng, Hartmut Koeppen, Howard M. Stern, Ralph Schwall, Avi Ashkenazi	51
3	Identification and immunotherapeutic targeting of antigens induced by chemotherapy 2006 ·Nature Biotechnology ·Bonnee Rubinfeld, (unknown), Suzanna Clark, Sharon Fong, (unknown), Hartmut Koeppen, Sarajane Ross, Paul Polakis	49
4	Apo2 Ligand/Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Cooperates with Chemotherapy to Inhibit Orthotopic Lung Tumor Growth and Improve Survival 2004 ·Cancer Research ·Hongkui Jin, Renhui Yang, Sharon Fong, Klára Tótpál, David A. Lawrence, Zhong Zheng, Jed Ross, Hartmut Koeppen, Ralph Schwall, Avi Ashkenazi	97
5	Selective cyclin-dependent kinase 2/cyclin A antagonists that differ from ATP site inhibitors block tumor growth. 2003 ·PubMed ·Nerissa Mendoza, Sharon Fong, (unknown), Hartmut Koeppen, Ralph Schwall, Dineli Wickramasinghe	59
6	Tumor-cell resistance to death receptor–induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax 2002 ·Nature Medicine ·Heidi Leblanc, David A. Lawrence, Eugene Varfolomeev, Klára Tótpál, John Morlan, Peter Schow, Sharon Fong, Ralph Schwall, Dominick Sinicropi, Avi Ashkenazi	431
7	Synergistic Induction of Tumor Antigens by Wnt-1 Signaling and Retinoic Acid Revealed by Gene Expression Profiling 2002 ·Journal of Biological Chemistry ·David A. Tice, Wayne Szeto, Irina Soloviev, Bonnee Rubinfeld, Sharon Fong, Debra L. Dugger, Jane Winer, P. Mickey Williams, (unknown), (unknown), Ralph Schwall, Diane Pennica, Paul Polakis	65
8	Safety and antitumor activity of recombinant soluble Apo2 ligand breakdown → 1999 ·Journal of Clinical Investigation ·Avi Ashkenazi, (unknown), Sharon Fong, Susan W.S. Leung, David A. Lawrence, Scot A. Marsters, (unknown), Ling Chang, (unknown), Andrea Hebert, Laura DeForge, Iphigenia L. Koumenis, (unknown), (unknown), Jeanine L. Bussiere, Hartmut Koeppen, Zahra Shahrokh, Ralph Schwall	1892
9	Strategies for manipulating apoptosis for cancer therapy with tumor necrosis factor and lymphotoxin 1996 ·Journal of Cellular Biochemistry ·G H Wong, Roger L. Kaspar, (unknown), Cathy S. Carlson, Sharon Fong, (unknown), Gordon A. Vehar	13
10	Anticuerpos monoclonales contra el antigeno carcino embrionario en ensayos inmunohistoquimicos e inmunoquimicos 1987 ·Jorge Gavilondo, (unknown), Sharon Fong, (unknown), Antonio Fernández, Carlos García, (unknown), (unknown)	1
11	Carcinoembryonic antigen fraction in lung cancer. 1983 ·PubMed ·Sharon Fong, León, (unknown), (unknown)	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact